報價延遲最少15分鐘:2025/01/11 17:29 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.78/-0.18
|
|
企業價值
127.94M
|
| 資產負債 |
|
每股賬面淨值
0.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:29 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others. |